跳至主要内容
临床试验/ACTRN12609000474257
ACTRN12609000474257已完成1 期

Single-Dose, four-way crossover, relative bioavailability study of Meloxicam Nanoformulation 7.5 mg Capsules and Mobic (Registered Trademark (R)) 7.5 mg Capsules in Healthy subjects under Fed and Fasted Condition

iCeutica Pty Ltd0 个研究点目标入组 14 人开始时间: 2009年6月17日最近更新:
适应症

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
14

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Randomised controlled trial
主要目的
Treatment
盲法
Blinded (masking used)

入排标准

年龄范围
18 Years 至 55 Years(—)
性别
All

入选标准

  • Available for entire study period.
  • Body mass index (BMI) between 18 kg/m2 and 30 kg/m2 and weighing at least 50 kg.
  • In good general health.

排除标准

  • History of hypersensitivity to naproxen, aspirin or related compounds.
  • History of gastrointestinal ulcers or bleeding.
  • History of surgery of the digestive tract (except for appendectomy).
  • Presence of any conditions that affect the absorption, metabolism or passage of drugs out of the body (e.g. sprue, coeliac disease, Crohn's disease, colitis, liver or kidney conditions).
  • Recent history (within 1 year) of mental illness, drug addiction, drug abuse or alcoholism.
  • Use of any drugs known to induce of inhibit hepatic drug metabolism within 30 days of planned dosing.
  • If femals, lactating, or positive pregnancy test at screening, or prior to each of the treatment periods.

研究者

发起方
iCeutica Pty Ltd

相似试验